Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/22172
Title: EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees.
Austin Authors: Witjes, J Alfred;Babjuk, Marek;Bellmunt, Joaquim;Bruins, H Maxim;De Reijke, Theo M;De Santis, Maria;Gillessen, Silke;James, Nicholas;Maclennan, Steven;Palou, Juan;Powles, Tom;Neuzillet, Yann;Oddens, Jorg R;Oldenburg, Jan;Osanto, Susanne;J G Oyen, Wim;Pacheco-Figueiredo, Luís;Pappot, Helle;Patel, Manish I;Pieters, Bradley R;Plass, Karin;Sengupta, Shomik ;Remzi, Mesut;Retz, Margitta;Richenberg, Jonathan;Rink, Michael;Roghmann, Florian;Rosenberg, Jonathan E;Rouprêt, Morgan;Rouvière, Olivier;Salembier, Carl;Salminen, Antti;Sherif, Amir;Sargos, Paul;Smeenk, Robert J;Smits, Anita;Stenzl, Arnulf;Thalmann, George N;Tombal, Bertrand;Turkbey, Baris;Lauridsen, Susanne Vahr;Valdagni, Riccardo;Ribal, Maria J;Der Heijden, Antoine G Van;Van Poppel, Hein;Vartolomei, Mihai D;Veskimäe, Erik;Vilaseca, Antoni;Rivera, Franklin A Vives;Wiegel, Thomas;Wiklund, Peter;Williams, Andrew;Zigeuner, Richard;Shariat, Shahrokh F;Horwich, Alan;Der Kwast, Theo Van;Xylinas, Evanguelos;Agarwal, Neeraj;Arends, Tom;Bamias, Aristotle;Birtle, Alison;Black, Peter C;Bochner, Bernard H;Bolla, Michel;Boormans, Joost L;Bossi, Alberto;Briganti, Alberto;Brummelhuis, Iris;Burger, Max;Castellano, Daniel;Cathomas, Richard;Chiti, Arturo;Choudhury, Ananya;Compérat, Eva;Crabb, Simon;Culine, Stephane;De Bari, Berardino;De Blok, Willem;J L De Visschere, Pieter;Decaestecker, Karel;Dimitropoulos, Konstantinos;Dominguez-Escrig, Jose L;Fanti, Stefano;Fonteyne, Valerie;Frydenberg, Mark;Futterer, Jurgen J;Gakis, Georgios;Geavlete, Bogdan;Gontero, Paolo;Grubmüller, Bernhard;Hafeez, Shaista;Hansel, Donna E;Hartmann, Arndt;Hayne, Dickon;Henry, Ann M;Hernandez, Virginia;Herr, Harry;Herrmann, Ken;Hoskin, Peter;Huguet, Jorge;Jereczek-Fossa, Barbara A;Jones, Rob;Kamat, Ashish M;Khoo, Vincent;Kiltie, Anne E;Krege, Susanne;Ladoire, Sylvain;Lara, Pedro C;Leliveld, Annemarie;Linares-Espinós, Estefania;Løgager, Vibeke;Lorch, Anja;Loriot, Yohann;Meijer, Richard;Mir, M Carmen;Moschini, Marco;Mostafid, Hugh;Müller, Arndt-Christian;Müller, Christoph R;N'Dow, James;Necchi, Andrea
Affiliation: Division of Oncology and Haematology, Kantonsspital St Gallen, St Gallen, Switzerland
Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands
Division of Cancer Sciences, University of Manchester, Manchester, UK
The Christie NHS Foundation Trust, Manchester, UK
The Royal Free NHS Trust, London, UK
Barts Cancer Institute, Queen Mary University of London, London, UK
Department of Oncology, Hospital Universitario San Roque
Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Department of Oncology and Hemato-oncology, University of Milan, Milan
Mount Vernon Centre for Cancer Treatment, London, UK
Department of Clinical Oncology, The Royal Marsden NHS Foundation Trust, London, UK
Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK
Radiation Oncology Department, Centre Hospitalier Universitaire Vaudois, Université de Lausanne, Lausanne, Switzerland
Radiation Oncology Department, Centre Hospitalier Régional Universitaire "Jean Minjoz" of Besançon, INSERM UMR 1098, Besançon, France
Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy
Department of Urology, Urological Research Institute, Milan
Rosemere Cancer Centre, Lancashire Teaching Hospitals, Preston, UK
Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
University of Bern, Bern, Switzerland
Division of Cancer Sciences, University of Manchester, Manchester, UK
Department of Urology, Charité University Hospital, Berlin, Germany
Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
Humanitas Research Hospital, Milan, Italy
Department of Biomedical Sciences, Humanitas University, Milan, Italy
Faculty of Medicine, University of Oslo, Oslo, Norway
Department of Oncology, Akershus University Hospital, Lørenskog, Norway
Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK
Academic Urology Unit, University of Aberdeen, Aberdeen, UK
Brighton and Sussex Medical School, Brighton, UK
Department of Imaging and Nuclear Medicine, Royal Sussex County Hospital, Brighton, UK
Universidad Fernando Pessoa, Canarias, Spain
Department of Urology, Weill Cornell Medical College, New York, New York, USA
Department of Urology, Medical University of Vienna, Vienna, Austria
Depatment of Urology, 2nd Faculty of Medicine, Hospital Motol, Charles University, Prague, Czech Republic
Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal
Department of Urology, Centro Hospitalar São João, Porto, Portugal
Department of Radiology and Nuclear Medicine, Rijnstate Hospital, Arnhem, The Netherlands
Department of Medicine, University of Melbourne; Monash University, Melbourne, Australia
Division of Radiotherapy, IEO European Institute of Oncology, IRCCS, Milan, Italy
Eastern Health Clinical School, Monash University, Melbourne, Australia
Department of Surgery, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Department of Urology, Weill Cornell Medical College, New York, New York, USA
Urology Service, Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Weill Cornell Medical College, New York, New York, USA
Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France
Department of Urology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
Department of Urology, University Hospital La Paz, Madrid, Spain
Department of Radiology, Copenhagen University Hospital Herlev and Gentofte, Herlev, Denmark
Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland
Département de Médecine Oncologique, Gustave Roussy, INSERM U981, Université Paris-Sud, Université Paris-Saclay, Villejuif, France
UMC Utrecht Cancer Center, MS Oncologic Urology, Utrecht, The Netherlands
Servicio de Urología, Fundación Instituto Valenciano de Oncología, Valencia, Spain
Department of Urology, Luzerner Kantonsspital, Luzern, Switzerland
Department of Urology, Royal Surrey County Hospital, Guildford, UK
Department of Radiation Oncology, Eberhard Karls University, Tübingen, Germany
Cancer Treatment Centre, Sorlandet Hospital, Kristiansand, Norway
Department of Medical Oncology, Istituto Nazionale Tumori of Milan, Milan, Italy
Department of Urology, Hospital Foch, University of Versailles-Saint-Quentin-en-Yvelines, Suresnes, France
Department of Urology, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands
Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Department of Oncology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark
Department of Urology, Westmead Hospital, University of Sydney, Sydney, Australia
Department Radiation Oncology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands
EAU Guidelines Office, Arnhem, The Netherlands
Department of Urology, Medical University of Vienna, Vienna, Austria
Department of Urology, Rechts der Isar Medical Center, Technical University of Munich, Munich, Germany
Department of Urology, Ruhr-University Bochum, Marien Hospital, Herne, Germany
Department of Urology, Sorbonne Université, GRC n°5, ONCOTYPE-URO, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France
Hospices Civils de Lyon, Service d'Imagerie Urinaire et Vasculaire, Hôpital Edouard Herriot, Lyon, France; Université de Lyon, Université Lyon 1, faculté de médecine Lyon Est, Lyon, France
Department of Radiation Oncology, Europe Hospitals Brussels, Belgium
Department of Urology, University Hospital of Turku, Finland
Department of Radiotherapy, Institut Bergonié, Bordeaux, France
Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå university, Umeå, Sweden
Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands
Icahn School of Medicine, Mount Sinai Health System New York City, New York, USA
Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands
Department of Urology, Eberhard Karls University Tübingen, Tübingen, Germany
Department of Urology, Inselspital, Bern University Hospital, Bern, Switzerland
Division of Urology, IREC, Cliniques Universitaires Saint Luc, UCL, Brussels, Belgium
Molecular Imaging Program, National Cancer Institute, Bethesda, Maryland, USA
Department of Urology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Department of Oncology and Hemato-oncology, Università degli Studi di Milano, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands
Department of Urology, University Hospitals Leuven, Belgium
Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Cell and Molecular Biology, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Romania
Department of Urology, Karolinska Institutet, Stockholm, Sweden
Department of Urology, Tampere University Hospital, Tampere, Finland
Uro-Oncology Unit, Hospital Clinic, University of Barcelona, Spain
Clinica HematoOncologica Bonadona Prevenir, Universidad Metropolitana, Clinica Club de Leones, Barranquilla, Colombia
Department of Radiation Oncology, University Hospital Ulm, Ulm, Germany
Department of Urology, Auckland City Hospital, Auckland, New Zealand
Department of Urology, Medizinische Universität Graz, Graz, Austria
Emeritus Professor, The Institute of Cancer Research, London, UK
IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain; Harvard Medical School, Boston, Massachusetts, USA
Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands
Department of Urology, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands
Academic Urology Unit, University of Aberdeen, Aberdeen, UK
Department of Urology, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain
Uro-Oncology Unit, Hospital Clinic, University of Barcelona, Spain
Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
Department of Urology, Bichat-Claude Bernard Hospital, Assistance Publique Hôpitaux de Paris, Paris, France; Paris Descartes University, Paris, France
Huntsman Cancer Institute, University of Utah (NCI-CCC), Salt Lake City, Utah, USA
Urology Department, Canisius-Wilhelmina Ziekenhuis Nijmegen, The Netherlands
2nd Propaedeutic Dept of Internal Medicine, Medical School, National & Kapodistrian University of Athens, Athens, Greece
Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, British Colombia, Canada
Emeritus Professor of Radiation Oncology, Grenoble - Alpes University, Grenoble, France
Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands
Department of Radiation Oncology, Gustave Roussy Institute, Villejuif, France
Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands
Department of Urology, Caritas-St. Josef Medical Center, University of Regensburg, Regensburg, Germany
Medical Oncology Department, 12 de Octubre University Hospital (CIBERONC), Madrid, Spain
Departement Innere Medizin, Abteilung Onkologie und Hämatologie, Kantonsspital Graubünden, Chur, Switzerland
Department of Biomedical Sciences, Humanitas University, Milan, Italy; Humanitas Research Hospital, Milan, Italy
Department of Pathology, Tenon hospital, HUEP, Paris, France; Sorbonne University, Paris, France
Cancer Sciences Unit, University of Southampton, Southampton, UK
Department of Cancer Medicine, Hôpital Saint Louis, Paris, France
Department of Urology, University Medical Center Utrecht, Utrecht, The Netherlands
Department of Radiology and Nuclear Medicine, Division of Genitourinary Radiology and Mammography, Ghent University Hospital, Ghent, Belgium
Department of Urology, Ghent University Hospital, Ghent, Belgium
Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK
Servicio de Urología, Fundación Instituto Valenciano de Oncología, Valencia, Spain
Department of Nuclear Medicine, Policlinico S Orsola, University of Bologna, Italy
Department of Radiotherapy Oncology, Ghent University Hospital, Ghent, Belgium
Department of Surgery, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Australia
Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
Department of Urology and Paediatric Urology, University Hospital of Würzburg, Julius-Maximillians University, Würzburg, Germany
Department of Urology, Saint John Emergency Clinical Hospital, Bucharest, Romania
Division of Urology, Molinette Hospital, University of Studies of Torino, Torino, Italy
Department of Urology, Medical University of Vienna, Vienna, Austria
Department of Urology, University of California, San Diego Pathology, La Jolla, California, USA
Institute of Pathology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg, Erlangen, Germany
Department of Urology, UWA Medical School, University of Western Australia, Perth, Australia
Leeds Institute of Medical Research, University of Leeds, Leeds, UK
Department of Urology, Hospital Universitario Fundación de Alcorcón, Madrid, Spain
Urology Service, Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Department of Nuclear Medicine, Universitätsklinikum Essen, Essen, Germany
Department of Urology, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain
Institute of Cancer Sciences, College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
Department of Urology - Division of Surgery, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK
Department of Urology, Pediatric Urology and Urologic Oncology, Kliniken Essen-Mitte, Essen, Germany
Issue Date: Feb-2020
metadata.dc.date: 2019-11-19
Publication information: European urology 2020; 77(2): 223-250
Abstract: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference. Online Delphi survey and consensus conference. The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), and 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). Overall, 116 statements were included in the Delphi survey. Of these statements, 33 (28%) achieved level 1 consensus and 49 (42%) achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease, and the evolving role of checkpoint inhibitor therapy in metastatic disease. These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time when further evidence is available to guide our approach. This report summarises findings from an international, multistakeholder project organised by the EAU and ESMO. In this project, a steering committee identified areas of bladder cancer management where there is currently no good-quality evidence to guide treatment decisions. From this, they developed a series of proposed statements, 71 of which achieved consensus by a large group of experts in the field of bladder cancer. It is anticipated that these statements will provide further guidance to health care professionals and could help improve patient outcomes until a time when good-quality evidence is available.
URI: http://ahro.austin.org.au/austinjspui/handle/1/22172
DOI: 10.1016/j.eururo.2019.09.035
ORCID: 0000-0003-3357-1216
PubMed URL: 31753752
Type: Journal Article
Subjects: Bladder cancer
Consensus
Delphi
Diagnosis
Follow-up
Treatment
Appears in Collections:Journal articles

Show full item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.